Oncolytics Biotech Inc.
Oncolytics Biotech Inc.
Your view on ONCY
Overview
What the company does, where it operates, and who runs it.
About Oncolytics Biotech Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jared Kelly
- Headquarters
- 322 11th Avenue SW, Calgary, AB, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jared Kelly
- Headquarters
- 322 11th Avenue SW, Calgary, AB, CA
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.
Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC.
The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Oncolytics Biotech Inc., and the rating behind it. ONCY last traded at $0.75; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Oncolytics Biotech Inc.. Starting points for Oncolytics Biotech Inc.: EPS -$0.32, beta 1.15 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Oncolytics Biotech Inc.. Oncolytics Biotech Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Oncolytics Biotech Inc.. Trailing twelve-month EPS for Oncolytics Biotech Inc. stands at -$0.32. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Oncolytics Biotech Inc.. Oncolytics Biotech Inc. has reported as a listed company since 2001. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Oncolytics Biotech Inc. valued side by side against its closest peers. Oncolytics Biotech Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Oncolytics Biotech Inc., and how their positions are changing. At a $74.8M market value, institutional positions materially move Oncolytics Biotech Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Oncolytics Biotech Inc. executives and directors. Shares of Oncolytics Biotech Inc. have traded between $0.33 and $1.51 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Oncolytics Biotech Inc.. Oncolytics Biotech Inc. is a $74.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Oncolytics Biotech Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Oncolytics Biotech Inc.. Coverage tracks Oncolytics Biotech Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.